MedTrace Logo

A Retrospective Chart Review Study of the Outcomes of 2nd Line Therapy With LEn/Dex in Greek Patients With R/R Multiple MyEloma and the Treatment PatterNs Following Progressive Disease

NCT02608515 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 207

Last updated 2018-05-22

No results posted yet for this study

Summary

This non-interventional retrospective chart review study aims to evaluate the clinical outcomes of patients with RRMM receiving lenalidomide/dexamethasone (Len/Dex) treatment at 1st relapse and the treatment patterns following progressive disease as part of the routine clinical practice in Greece.

Conditions

Sponsors & Collaborators

  • Genesis Pharma S.A.

    lead INDUSTRY

Principal Investigators

  • Kiki Karvounis · Medical Department of Genesis Pharma SA

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-12-31
Primary Completion
2016-09-30
Completion
2016-09-30

Countries

  • Greece

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02608515 on ClinicalTrials.gov